Processes to modulate the activity of knfb, to identify a compound or compounds capable of directly or indirectly modulating the activity of p105, to identify a reference compound for a pharmaceutical product usable in the treatment of disease involving or using an inflammatory response, identifiable compound antibody, polypeptide, and, processes to modulate p105 activity in a cell, use of a compound, to identify a compound that regulates an inflammatory response mediated by tpl-2, to identify a compound that regulates signal transduction by tpl-2, to identify a compound that modulates the interaction of a tpl-2 polypeptide with a target component of modulation of tpl-2, to treat an immune system condition in a patient in need of it by modulating tpl- activity 2, to treat a tpl-2-mediated condition in a patient, and to modulate tpl-2-mediated nfkb regulation in a patient in need hence, process to treat rheumatoid arthritis.

摘要

"PROCESSES TO MODULATE THE ACTIVITY OF NFkB, TO IDENTIFY A COMPOUND OR COMPOUNDS ABLE TO, DIRECTLY OR INDIRECTLY, MODULAR THE ACTIVITY OF THE P105, TO IDENTIFY A COMPOUND OF REFERENCE FOR A PHARMACEUTICAL PRODUCT USED IN THE TREATMENT OF A HARMFUL INFLUENCE WHICH WAS A LOSS OF A WASTE AGAIN. , IDENTIFIABLE COMPOUND ANTIBODY, POLYPEPTIDE, AND, PROCESSES TO MODULATE THE ACTIVITY OF THE P105 IN A CELL, USE OF A COMPOUND, TO IDENTIFY A COMPOUND THAT REGULATES AN INFAMMATORY RESPONSE MEASURED BY TPL-2, TO IDENTIFY A COMPOUND THAT REGULATES THE NORMAL COMPOSITION MEDIATED BY TPL-2, TO IDENTIFY A COMPOUND THAT REGULATES SIGNAL TRANSDUCTION BY TPL-2, TO IDENTIFY A COMPOUND THAT MODULATES THE INTERACTION OF A TPL-2 POLYPEPTIDE WITH A TPL-2 MODULATION TARGET COMPONENT, TO TREAT A CONDITION OF THE IMMUNE SYSTEM IN A PATIENT IN NEED OF THIS BY MODULATING THE ACTIVITY OF TPL-2, TO TREAT A CONDITION MEDIATED BY TPL-2 IN A PATIENT, AND TO MODULATE NFkB REGULATION MEDIATED BY TPL-2 IN A PATIENT IN NEED OF THIS, PROCESS TO TREAT RHEUMATOID ARTHRITIS ". it is shown that TPL-2 is responsible for the phosphorylation of p105 and its resulting proteolysis, which leads to p50 Rel translocation to the nucleus. Consequently, the invention provides TPL-2 as a specific regulator of NFkB activation and as a modulator of inflammatory responses in which p105 is involved and as a target for the development of compounds capable of influencing NFkB activation.